$RGLS
Regulus Therapeutics Inc.

2018 Q3 Form 10-Q Financial Statement

#000162828018010974 Filed on August 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $18.00K $18.00K $18.00K
YoY Change 0.0% 0.0% -96.27%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.990M $3.350M $7.060M
YoY Change 9.12% -52.55% 92.9%
% of Gross Profit
Research & Development $6.879M $10.01M $14.28M
YoY Change -45.82% -29.87% -20.71%
% of Gross Profit
Depreciation & Amortization $550.0K $560.0K $660.0K
YoY Change -5.17% -15.15% 29.41%
% of Gross Profit
Operating Expenses $9.872M $13.36M $21.34M
YoY Change -36.03% -37.37% -1.55%
Operating Profit -$9.854M -$13.34M -$21.32M
YoY Change -36.08% -37.4% 0.61%
Interest Expense $620.0K $621.0K $603.0K
YoY Change 6.9% 2.99% 570.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$10.27M -$13.85M -$21.74M
YoY Change -35.12% -36.29% 3.02%
Income Tax $0.00 $0.00 -$128.0K
% Of Pretax Income
Net Earnings -$10.27M -$13.85M -$21.61M
YoY Change -35.1% -35.92% 2.46%
Net Earnings / Revenue -57072.22% -76927.78% -120044.44%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.180M -$1.594M -$4.878M
COMMON SHARES
Basic Shares Outstanding 104.8M shares 104.3M shares 53.18M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.50M $32.90M $40.10M
YoY Change -71.29% -17.96% -62.7%
Cash & Equivalents $14.08M $13.49M $12.54M
Short-Term Investments $6.400M $19.40M $27.50M
Other Short-Term Assets $717.0K $1.536M $3.018M
YoY Change -59.08% -49.11% 478.16%
Inventory
Prepaid Expenses $4.194M $4.655M $6.149M
Receivables $0.00 $200.0K $700.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $25.44M $39.23M $49.94M
YoY Change -68.03% -21.45% -57.03%
LONG-TERM ASSETS
Property, Plant & Equipment $8.324M $8.906M $10.75M
YoY Change -18.17% -17.18% -12.73%
Goodwill
YoY Change
Intangibles $676.0K $705.0K $823.0K
YoY Change -15.71% -14.34% -22.5%
Long-Term Investments
YoY Change
Other Assets $327.0K $328.0K $340.0K
YoY Change 6.51% -3.53% 9.68%
Total Long-Term Assets $9.327M $9.939M $11.92M
YoY Change -17.32% -16.59% -12.98%
TOTAL ASSETS
Total Short-Term Assets $25.44M $39.23M $49.94M
Total Long-Term Assets $9.327M $9.939M $11.92M
Total Assets $34.77M $49.17M $61.86M
YoY Change -61.73% -20.51% -52.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.235M $5.468M $4.901M
YoY Change -76.38% 11.57% 39.87%
Accrued Expenses $1.856M $2.090M $4.717M
YoY Change -61.09% -55.69% -13.8%
Deferred Revenue $72.00K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $19.10M $19.90M
YoY Change
Total Short-Term Liabilities $25.65M $30.80M $11.12M
YoY Change 118.18% 176.89% 0.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $19.80M
YoY Change -100.0% -100.0% 0.0%
Other Long-Term Liabilities $373.0K $437.0K $283.0K
YoY Change 6.27% 54.42% -96.7%
Total Long-Term Liabilities $373.0K $437.0K $283.0K
YoY Change 6.27% 54.42% -96.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.65M $30.80M $11.12M
Total Long-Term Liabilities $373.0K $437.0K $283.0K
Total Liabilities $33.19M $38.74M $41.87M
YoY Change -21.47% -7.47% 0.92%
SHAREHOLDERS EQUITY
Retained Earnings -$384.2M -$373.9M -$315.6M
YoY Change 15.92% 18.48% 34.97%
Common Stock $385.8M $384.4M $335.7M
YoY Change 1.5% 14.52% 4.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.578M $10.43M $20.00M
YoY Change
Total Liabilities & Shareholders Equity $34.77M $49.17M $61.86M
YoY Change -61.73% -20.51% -52.39%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$10.27M -$13.85M -$21.61M
YoY Change -35.1% -35.92% 2.46%
Depreciation, Depletion And Amortization $550.0K $560.0K $660.0K
YoY Change -5.17% -15.15% 29.41%
Cash From Operating Activities -$11.45M -$12.21M -$17.33M
YoY Change -1.8% -29.54% -0.12%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K $0.00 $20.00K
YoY Change -80.0% -100.0% -84.62%
Acquisitions
YoY Change
Other Investing Activities $12.95M $15.71M $14.96M
YoY Change -154.64% 5.01% 189.36%
Cash From Investing Activities $12.93M $15.71M $14.98M
YoY Change -154.33% 4.87% 182.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -890.0K -70.00K 0.000
YoY Change -102.06% -100.0%
NET CHANGE
Cash From Operating Activities -11.45M -12.21M -17.33M
Cash From Investing Activities 12.93M 15.71M 14.98M
Cash From Financing Activities -890.0K -70.00K 0.000
Net Change In Cash 590.0K 3.430M -2.350M
YoY Change -92.33% -245.96% -130.21%
FREE CASH FLOW
Cash From Operating Activities -$11.45M -$12.21M -$17.33M
Capital Expenditures -$20.00K $0.00 $20.00K
Free Cash Flow -$11.43M -$12.21M -$17.35M
YoY Change -1.12% -29.63% -0.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001505512
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
104797517 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
REGULUS THERAPEUTICS INC.
dei Trading Symbol
TradingSymbol
RGLS
CY2018Q2 rgls Cashand Cash Equivalentsand Marketable Securities
CashandCashEquivalentsandMarketableSecurities
32900000 USD
rgls Proceeds From Capital Lease Financing
ProceedsFromCapitalLeaseFinancing
0 USD
rgls Proceeds From Capital Lease Financing
ProceedsFromCapitalLeaseFinancing
417000 USD
CY2017Q4 rgls Rent Less Current Portion Liability
RentLessCurrentPortionLiability
8072000 USD
CY2018Q2 rgls Rent Less Current Portion Liability
RentLessCurrentPortionLiability
7459000 USD
CY2017Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
373000 USD
CY2018Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
184000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5743000 USD
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5468000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-181000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-87000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2995000 USD
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2090000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-134000 USD
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-80000 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
381104000 USD
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
384296000 USD
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2865000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5247000 USD
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1357000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2984000 USD
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2140111 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2869643 shares
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6146138 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6801848 shares
CY2017Q4 us-gaap Assets
Assets
77809000 USD
CY2018Q2 us-gaap Assets
Assets
49170000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
66736000 USD
CY2018Q2 us-gaap Assets Current
AssetsCurrent
39231000 USD
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
57402000 USD
CY2018Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
30835000 USD
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2018Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
77000 USD
CY2018Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
23000 USD
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
46632000 USD
CY2018Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
19394000 USD
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
46555000 USD
CY2018Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
19371000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
110000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
22000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14941000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12538000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13519000 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13485000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2403000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-34000 USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17620000 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
103955147 shares
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104424492 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
103955147 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104424492 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
104000 USD
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
104000 USD
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21598000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41593000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13800000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29819000 USD
CY2018Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
77000 USD
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1921000 USD
CY2018Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
42000 USD
CY2017Q4 us-gaap Debt Current
DebtCurrent
19859000 USD
CY2018Q2 us-gaap Debt Current
DebtCurrent
19888000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1357000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1121000 USD
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1985000 USD
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1223000 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7057000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11016000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3349000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7122000 USD
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21736000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41761000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-231000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
597000 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13847000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29872000 USD
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-128000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-132000 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-967000 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-189000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-907000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-276000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-814000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-927000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-36000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-36000 USD
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-187000 USD
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-787000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-885000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-761000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1106000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-128000 USD
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
775000 USD
CY2018Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
705000 USD
CY2017Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
184000 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
398000 USD
CY2018Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
118000 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
282000 USD
CY2017Q2 us-gaap Interest Expense
InterestExpense
603000 USD
us-gaap Interest Expense
InterestExpense
1149000 USD
CY2018Q2 us-gaap Interest Expense
InterestExpense
621000 USD
us-gaap Interest Expense
InterestExpense
1227000 USD
us-gaap Interest Paid
InterestPaid
946000 USD
us-gaap Interest Paid
InterestPaid
1045000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
42593000 USD
CY2018Q2 us-gaap Liabilities
Liabilities
38737000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77809000 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49170000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32600000 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
30799000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
268000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
626000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33336000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27151000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36007000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27811000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-21608000 USD
us-gaap Net Income Loss
NetIncomeLoss
-41629000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-13847000 USD
us-gaap Net Income Loss
NetIncomeLoss
-29873000 USD
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0 USD
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
306000 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
21335000 USD
us-gaap Operating Expenses
OperatingExpenses
41046000 USD
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
13362000 USD
us-gaap Operating Expenses
OperatingExpenses
28963000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21317000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-41010000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13344000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-28927000 USD
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1506000 USD
CY2018Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1536000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
590000 USD
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
328000 USD
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
36000 USD
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
47000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
54000 USD
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2018000 USD
CY2018Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2130000 USD
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
437000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
190000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
109000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
16000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
124000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4453000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4783000 USD
CY2018Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4655000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
265000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
208000 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
37929000 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
27151000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9708000 USD
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8906000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14278000 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.98
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30030000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10013000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21841000 USD
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1300000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345858000 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-373887000 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-344014000 USD
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36000 USD
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5247000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2984000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2995000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
7165000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10649000 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14815000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.44
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.45
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.38
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
46555000 USD
CY2018Q2 us-gaap Short Term Investments
ShortTermInvestments
19371000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
4000 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
35216000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
10433000 USD
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53182330 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53086887 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
104319555 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
104169746 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001628280-18-010974-index-headers.html Edgar Link pending
0001628280-18-010974-index.html Edgar Link pending
0001628280-18-010974.txt Edgar Link pending
0001628280-18-010974-xbrl.zip Edgar Link pending
ex-101xazletteragreement.htm Edgar Link pending
ex-311x20180630.htm Edgar Link pending
ex-312x20180630.htm Edgar Link pending
ex-321x20180630.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgls-20180630.xml Edgar Link completed
rgls-20180630.xsd Edgar Link pending
rgls-20180630_cal.xml Edgar Link unprocessable
rgls-20180630_def.xml Edgar Link unprocessable
rgls-20180630_lab.xml Edgar Link unprocessable
rgls-20180630_pre.xml Edgar Link unprocessable
rgls20180630-10q.htm Edgar Link pending
Show.js Edgar Link pending